{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-006238","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.220676+00:00","generated_at":"2026-06-16T12:43:11.561217+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Q1 revenue $287.6M; proprietary products up 25% YoY; GAAP EPS -$0.25, non-GAAP EPS $0.01","bullets":["Proprietary product net sales $214.7M (+25% YoY); LYBALVI grew 173% to $38.0M.","GAAP net loss $41.8M ($0.25 loss/share) vs $35.9M loss prior year.","Non-GAAP net income $2.4M ($0.01 EPS) vs $19.6M ($0.12) prior year.","Oncology separation on track for H2 2023; new company to be Mural Oncology.","Favorable second interim award in Janssen arbitration; ~$194M back royalties due."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-006238","json":"https://secwatch.observer/filing/0001564590-23-006238.json","markdown":"https://secwatch.observer/filing/0001564590-23-006238.md","text":"https://secwatch.observer/filing/0001564590-23-006238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/0001564590-23-006238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/alks-8k_20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:43:11.561217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"251a96483ed3ceb3c4770188ce39c61660dbc9b5","claim":"Alkermes plc. reported three months ended March 31, 2023 results: revenue $287.6 million, net income $41.8 million, EPS $0.25 loss per share. Guidance reaffirmed.","evidence_excerpt":"Alkermes plc Reports First Quarter 2023 Financial Results — First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio — — GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 — — Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 — — Second Favorable Interim Award Received in Janssen Arbitration — — Financial Expectations for 2023 Reiterated —","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/0001564590-23-006238-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Revenue","value":"$287.6 million"},{"label":"Net income","value":"$41.8 million"},{"label":"EPS","value":"$0.25 loss per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}